{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:19Z","timestamp":1790882359120,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114008","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:59:48Z","timestamp":1710147588000},"page":"114008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma"],"prefix":"10.1016","volume":"202","author":[{"given":"Xiaoting","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114008_bib1","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.3390\/cancers14153779","article-title":"Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies","volume":"14","author":"Rager","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114008_bib2","first-page":"63","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci"},{"key":"10.1016\/j.ejca.2024.114008_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.114008_bib4","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3382","article-title":"Intra-patient heterogeneity of BRAF and NRAS molecular alterations in primary melanoma and metastases","volume":"100","author":"Pellegrini","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2024.114008_bib5","unstructured":"Dean L. Vemurafenib therapy and BRAF and NRAS genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda, MD: National Center for Biotechnology Information (US); 2012)."},{"key":"10.1016\/j.ejca.2024.114008_bib6","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: What do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: Towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.114008_bib8","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1038\/onc.2017.189","article-title":"Melanocytic nevi and melanoma: unraveling a complex relationship","volume":"36","author":"Damsky","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2024.114008_bib9","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ejca.2024.114008_bib10","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.2147\/OTT.S278095","article-title":"Current perspectives and novel strategies of NRAS-mutant melanoma","volume":"14","author":"Garcia-Alvarez","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2024.114008_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.114008_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/ol.2022.13613","article-title":"Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma","volume":"25","author":"Zablocka","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejca.2024.114008_bib13","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/cells10092216","article-title":"Prognostic roles of BRAF, KIT, NRAS, IGF2R and SF3B1 mutations in mucosal melanomas","volume":"10","author":"Wr\u00f3blewska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2024.114008_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2024.114008_bib15","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21147\/j.issn.1000-9604.2022.04.02","article-title":"National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)","volume":"34","author":"National Health Commission Of The People's Republic Of China","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ejca.2024.114008_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2024.114008_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2018.04.010","article-title":"MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients","volume":"98","author":"Kirchberger","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114008_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/cancers13030475","article-title":"No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: an Italian melanoma intergroup (IMI) study","volume":"13","author":"Guida","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114008_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-022-02287-3","article-title":"Targeted therapies for cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2024.114008_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1758834017708160","article-title":"Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date","volume":"9","author":"Boespflug","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2024.114008_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib24","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cancers12071727","article-title":"Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: phase II, randomized, controlled trial with crossover","volume":"12","author":"Lebb\u00e9","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114008_bib25","article-title":"Preclinical Characterization of Tunlametinib (HL-085), a Novel, Potent, and Selective MEK Inhibitor","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2024.114008_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12916-022-02669-7","article-title":"First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2024.114008_bib27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2013.79","article-title":"A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma","volume":"21","author":"Cui","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2024.114008_bib28","article-title":"Association of NRAS mutation with clinical outcomes of anti-PD-1 monotherapy in advanced melanoma: a pooled analysis of four Asian clinical trials","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2024.114008_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib31","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-13-3270","article-title":"Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114008_bib32","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.jid.2016.06.011","article-title":"NRAS, NRAS, which mutation is fairest of them all?","volume":"136","author":"Grill","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"49","key":"10.1016\/j.ejca.2024.114008_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208900119","article-title":"MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas","volume":"119","author":"Stopfer","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2024.114008_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.08.005","article-title":"A first-in-human, phase 1a dose-escalation study of the selective MEK1\/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma","volume":"175","author":"Mao","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114008_bib35","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114008_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:10:19Z","timestamp":1727410219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"alternative-id":["S0959804924001643"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114008"}}